As we move into 2023, there are several exciting new developments that have implications for adult vaccine availability, coverage and access. These include not only the new policy changes included in the Inflation Reduction Act of 2022 (IRA) that expand and improve adult vaccine coverage for Medicare and Medicaid beneficiaries, but also the promise of new advancements in vaccine innovation for diseases such as respiratory syncytial virus (RSV).

The COVID - 19 pandemic had a significant impact on decreasing routine immunization rates both for children and adults — but it also provided lessons learned on how to address equity issues and system barriers that can be leveraged moving forward to improve rates.This is especially important to protect against respiratory diseases as we saw this year with the “tripledemic.”

Although recommended vaccines, excluding flu for adults, on average remain below pre - pandemic levels, building on these new developments in 2023 can drive improvements.There is also a tremendous opportunity now to re - envision a more systematic approach to adult vaccination by maximizing uptake to create healthier communities and a more resilient public health infrastructure.

To learn more on the most recent insights updated on the platform, click here